Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients - 28/07/20
, S. Zayet a, 1, ⁎ , A. Lohse b, J.-C. Balblanc b, J. Badie c, P.-Y. Royer a, L. Toko a, C. Mezher c, N.J. Kadiane-Oussou a, M. Bossert b, A.-M. Bozgan b, A. Charpentier b, M.-F. Roux d, R. Contreras d, I. Mazurier e, P. Dussert e, V. Gendrin a, T. Conrozier bFor the HNF Hospital Tocilizumab multidisciplinary team
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | No drugs have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. |
• | By neutralizing a key inflammatory factor in the cytokine release syndrome in COVID-19, tocilizumab (TCZ) can block the cytokine storm and reduce disease severity. |
• | Our case-control study found that even though patients treated with TCZ had more comorbidities and presented with more severe forms, death and/or ICU admissions were higher in patients without TCZ. |
• | This result strongly suggests that TCZ may reduce the number of ICU admissions and/or mortality in patients with severe SARS-CoV-2 pneumonia. |
Abstract |
Introduction |
No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment.
Method |
We conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: death and/or ICU admissions.
Results |
Patients with TCZ (n=20) had a higher Charlson comorbidity index (5.3 [±2.4] vs 3.4 [±2.6], P=0.014), presented with more severe forms (higher level of oxygen therapy at 13L/min vs 6L/min, P<0.001), and had poorer biological findings (severe lymphopenia: 676/mm3 vs 914/mm3, P=0.037 and higher CRP level: 158mg/L vs 105mg/L, P=0.017) than patients without TCZ (n=25). However, death and/or ICU admissions were higher in patients without TCZ than in the TCZ group (72% vs 25%, P=0.002).
Conclusion |
Despite the small sample size and retrospective nature of the work, this result strongly suggests that TCZ may reduce the number of ICU admissions and/or mortality in patients with severe SARS-CoV-2 pneumonia.
Le texte complet de cet article est disponible en PDF.Keywords : Tocilizumab, COVID-19, SARS-CoV-2, Mortality, Intensive care unit
Plan
Vol 50 - N° 5
P. 397-400 - août 2020 Retour au numéro
Article précédent
- Erratum to “Management and prevention of imported malaria in children. Update of the French guidelines” [Med Mal Infect 50 (2020) 127–140]
- C. Leblanc, C. Vasse, P. Minodier, P. Mornand, J. Naudin, B. Quinet, J.Y. Siriez, F. Sorge, N. de Suremain, M. Thellier, E. Kendjo, A. Faye, P. Imbert
- Management of seasonal influenza by family physicians
- P. Kuentzmann-Klein, M. Martinot
Bienvenue sur EM-consulte, la référence des professionnels de santé.